Citations

Showing 10 of 107969 citations.

Half-Life and Clearance of Cardiac Troponin I and Troponin T in Humans
Kristensen, Jonas Henrik , Hasselbalch, Rasmus Bo , Strandkjær, Nina , Jørgensen, Nicoline, Østergaard, Morten, Møller‐Sørensen, Hasse , Nilsson, Jens Christian , Kamstrup, Pia R. , Dahl, Morten , Bor, Mustafa Vakur , Rode, Line , Holmvang, Lene , Bang, Lia E., Forman, Julie Lyng , Jaffe, Allan S. , Thygesen, Kristian , Bundgaard, Henning , Iversen, Kasper , Møller-Sørensen, Peter Hasse , Afzal, Shoaib , Kamstrup, Pia Rørbæk , Dahl, Morten , Frikke-Schmidt, Ruth , Jørgensen, Niklas Rye , Rode, Line , Kjærgaard, Jesper , Forman, Julie , Dalhoff, Kim , Jaffe, Allan S. , Bundgaard, Henning , Iversen, Kasper Karmark , Jørgensen, Niklas Rye , Kjærgaard, Jesper

Mayo Clinic

Circulation | September 10, 2024 | Volume: 150 | Issue: 15 | Pages: 1187-1198

10.1161/circulationaha.123.066565 | PMID 39253802 Get It

BACKGROUND: Cardiac troponin (cTn) is key in diagnosing myocardial infarction (MI). After MI, the clinically observed half-life of cTn has been reported to be 7 to 20 hours, but this estimate reflects the combined elimination and simultaneous release of cTn from cardiomyocytes. More precise timing of myocardial injuries necessitates separation of these 2 components. We used a novel method for determination of isolated cTn elimination kinetics in humans. METHODS: Patients with MI were included within 24 hours after revascularization and underwent plasmapheresis to obtain plasma with a high cTn concentration. After at least 3 weeks, patients returned for an autologous plasma retransfusion followed by blood sampling for 8 hours. cTn was measured with 5 different high-sensitivity cTn assays. RESULTS: Of 25 included patients, 20 participants (mean age, 64.5 years; SD, 8.2 years; 4 women [20%]) received a retransfusion after a median of 5.8 weeks (interquartile range, 5.0–6.9 weeks) after MI. After retransfusion of a median of 620 mL (range, 180–679 mL) autologous plasma, the concentration of cTn in participants’ blood increased 4 to 445 times above the upper reference level of the 5 high-sensitivity cTn assays. The median elimination half-life ranged from 134.1 minutes (95% CI, 117.8–168.0) for the Elecsys high-sensitivity cTnT assay to 239.7 minutes (95% CI, 153.7–295.1) for the Vitros high-sensitivity cTnI assay. The median clearance of cTnI ranged from 40.3 mL/min (95% CI, 32.0–44.9) to 52.7 mL/min (95% CI, 42.2–57.8). The clearance of cTnT was 77.0 mL/min (95% CI, 45.2–95.0). CONCLUSIONS: This novel method showed that the elimination half-life of cTnI and cTnT was 5 to 16 hours shorter than previously reported. This indicates a considerably longer duration of cardiomyocyte cTn release after MI than previously thought. Improved knowledge of timing of myocardial injury may call for changes in the management of MI and other disorders with myocardial injury.
Shiftwork and Burnout Among Trauma Surgeons: A Preliminary Analysis of Trauma Surgeons’ Fatigue and Stress Related to Overnight Shifts
Kim, Joseph , Navarro, Sergio M. , Park, Myung S., Navarro, Sergio Michael , Kim, Joseph Y , Norasi, Hamid , Hallbeck, M. Susan

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | September 10, 2024 | Volume: 68 | Issue: 1 | Pages: 499-503

10.1177/10711813241263812 Get It

Burnout is a challenging issue among surgeons. Many factors have been linked to burnout, such as an inadequate work-life balance, high stress levels, and the frequency of on-call, overnight shifts. There is a lack of research on factors in surgeons’ daily lives associated with burnout. This study observed trauma surgeons with daily surveys assessing stress and fatigue over 9 days (6 day shifts, three night shifts). This study analyzes surgeons’ stress and fatigue levels. The study population was compared to the population of US critical care surgeons to ensure representativeness based on age, sex, and rates of burnout. Overnight shifts showed high stress and fatigue levels relative to off days, day shifts, the 3 days before, and the 3 days after overnight shifts. Days performing surgery were also more stressful and fatiguing than non-surgery work days and off days. Fatigue and stress levels were minimized during off days.
WATER versus WATER II 5‐year update: Comparing Aquablation therapy for benign prostatic hyperplasia in 30–80‐cm3 and 80–150‐cm3 prostates
Berjaoui, Mohamad Baker , Nguyen, David‐Dan , Almousa, Saud, Daher, Karim , Barber, Neil , Bidair, Mo, Gilling, Peter , Anderson, Paul , Zorn, Kevin C. , Badlani, Gopal , Humphreys, Mitch, Kaplan, Steven A. , Kaufman, Ronald P., Elterman, Dean , Desai, Mihir , Roehrborn, Claus, Bhojani, Naeem , Bidair, Mohamed

Mayo Clinic

BJUI Compass | September 10, 2024 | Volume: 5 | Issue: 11 | Pages: 1137-1147

10.1002/bco2.430 | PMID 39539565 Get It

AbstractObjectiveThis study aims to compare the long‐term outcomes of Aquablation for small‐to‐moderate (30–80 cm3) prostates with the outcomes for large (80–150 cm3) prostates at 5‐year follow up.MethodsThe Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue (WATER; NCT02505919) is a prospective, double‐blind, international clinical trial encompassing 116 patients, examining Aquablation versus transurethral resection of the prostate (TURP) for LUTS/BPH in prostates sized between 30 and 80 cm3. In parallel, WATER II (W‐II; NCT03123250), a prospective, multicentre, single‐arm international clinical trial, explores Aquablation outcomes in prostates ranging from 80 to 150 cm3. Baseline parameters and 60‐month outcomes were scrutinized using statistical analyses, including Students' t test, Wilcoxon tests for continuous variables, and Fisher's test for binary variables.ResultsThere is a significant improvement in International Prostate Symptom Score (IPSS) from baseline to 60 months in both WATER (22.9 to 7.0) and WATER II (23.2 to 6.8) (P = 0.852). Urinary flow rate (Qmax) increased in both groups from baseline to 60 months (WATER: 9.4 to 17.3 cc/s; WATER II: 8.7 to 17.1 cc/s) (P = 0.933). Immediate and sustained enhancements were observed in IPSS and Qmax. At 5 years, a notable percentage of patients in both groups were BPH medication‐free (WATER: 99%; WATER II: 94%) (P = 0.0517) and free from surgical retreatment (WATER: 95%; WATER II: 97%) (P = 0.508).ConclusionsThe 5‐year follow‐up affirms that Aquablation therapy exhibits sustained outcomes, minimal irreversible complications, and low retreatment rates for treating LUTS/BPH, irrespective of prostate volume ranging from 30 to 150 cm3.
Enhanced Two-Step LAMP-CRISPR Assay with an Engineered Zst Polymerase for Contamination-Free and Ultrasensitive DNA Detection
Xie, Yi , Zhang, Yuqian , Cao, Liqin , Shi, Jun , Ding, Xiong , Yin, Kun , Ding, Xiong , Yin, Kun , Jiang, Kai , Guo, Xiaokui

Mayo Clinic

Analytical Chemistry | September 9, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1021/acs.analchem.4c03965 | PMID 39250834 Get It

Why Do We Know So Little About Genitourinary Syndrome of Menopause?
Faubion, Stephanie S.

Mayo Clinic

Annals of Internal Medicine | September 9, 2024 | Volume: 177 | Issue: 10 | Pages: 1437-1438

10.7326/annals-24-01693 | PMID 39250802 Get It

Guidelines Recommending That Clinicians Advise Patients on Lifestyle Changes: A Popular but Questionable Approach to Improve Public Health
Johansson, Minna , Niklasson, Amanda , Albarqouni, Loai , Jørgensen, Karsten Juhl , Guyatt, Gordon, Montori, Víctor M. , Montori, Victor M , Guyatt, Gordon

Mayo Clinic

Annals of Internal Medicine | September 9, 2024 | Volume: 177 | Issue: 10 | Pages: 1425-1427

10.7326/annals-24-00283 | PMID 39250805 Get It

Metformin Improves Glycemic Control and Postprandial Metabolism and Enhances Postprandial Glucagon-Like Peptide 1 Secretion in Patients With Type 2 Diabetes and Heart Failure: A Randomized, Double-Blind, Placebo-Controlled Trial
Hošková, Eva , VELEBOVA, KATERINA, Veleba, Jiří , Beneš, Jan , Kuda, Ondřej , Segeťová, Markéta , Thieme, Lenka , Pelikánová, Terezie , Kahleová, Hana , Melenovský, Vojtěch , Borlaug, Barry A. , Čajka, Tomáš , Kopecký, Ján , Pelikánová, Terezie , Haluzı́k, Martin , Hill, Martin

Mayo Clinic

Clinical Diabetes | September 9, 2024 | Volume: 43 | Issue: 1 | Pages: 23-32

10.2337/cd24-0003 | PMID 39829685 Get It

This randomized trial tested the effect of metformin on glycemic control and cardiac function in patients with heart failure (HF) and type 2 diabetes while evaluating intestinal effects on selected gut microbiome products reflected by trimethylamine-N-oxide (TMAO) and gut-derived incretins. Metformin treatment improved glycemic control and postprandial metabolism and enhanced postprandial glucagon-like peptide 1 (GLP-1) secretion but did not influence cardiac function or the TMAO levels. Metabolic effects of metformin in HF may be mediated by an improvement in intestinal endocrine function and enhanced secretion of the gut-derived incretin GLP-1.
Proceedings of the 46 th Annual Upper Midwest Neuro-Ophthalmology Group Meeting
Poonja, Sabrina , Rattanathamsakul, Natthapon , MacIntosh, Peter W., Chen, John J. , Chen, John J , Rattanathamsakul, Natthapon

Mayo Clinic

Neuro-Ophthalmology | September 9, 2024 | Volume: 48 | Issue: 6 | Pages: 448-454

10.1080/01658107.2024.2392180 | PMID 39583025 Get It

Navigating the Postoperative Management of Remifentanil-Induced Hyperalgesia: A Case Report
Smith, Nathan T. , Fernholz, Ryan, Juresic, Sanny

Mayo Clinic

Journal of Pain & Palliative Care Pharmacotherapy | September 9, 2024 | Volume: 38 | Issue: 4 | Pages: 373-378

10.1080/15360288.2024.2400901 | PMID 39250604 Get It

Social Isolation and Healthcare Utilization in Older Adults Living With Dementia and Mild Cognitive Impairment in the United States
Bartley, Mairead M. , Schroeder, Darrell R. , Khera, Nandita , Griffin, Joan M. , Griffin, Joan M , Schroeder, Darrell , Sauver, Jennifer L. St.

Mayo Clinic

Innovation in Aging | September 9, 2024 | Volume: 8 | Issue: 10 | Pages: No page available

10.1093/geroni/igae081 | PMID 39430370 Get It

Abstract Background and Objectives Social isolation is commonly experienced by older people and is associated with adverse health outcomes. Little is known about the influence of social isolation on the risk of acute care utilization among people living with mild cognitive impairment (MCI) or dementia. Our objective was to investigate the impact of social isolation on the risk of death, hospitalization, and emergency department (ED) use among people living with MCI or dementia who are followed in our Community Internal Medicine practice at Mayo Clinic, Rochester, Minnesota. Research Design and Methods We included people living with MCI or dementia, 55 years and older, who had a clinic visit between June 1, 2019, and June 30, 2021, and who had completed questions about social connections. The risk of death, hospitalization, and ED use was examined by levels of social connection (socially isolated, moderately isolated, moderately integrated, or socially integrated). Results Of 2,320 people included (1,010 with MCI and 1,310 with dementia), 455 (19.6%) were classified as socially isolated and 591 (25.5%) were moderately isolated. Compared with those who were socially integrated, people who were socially isolated were at higher risk of death, hospitalization, and ED visits (p < .001). Discussion and Implications Social isolation is associated with an increased risk of acute health care utilization and death in people living with MCI or dementia. Interventions to address social isolation in this population are needed.